Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06985238 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stratagen Quantitative Prostate MRI Platform Pilot Study

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 8 months later Mar 31, 2026 → Nov 30, 2026
See other at-risk trials from Stratagen Bio, Inc.

Record History

  1. Primary completion pushed from Mar 31, 2026 to Nov 30, 2026 Enrollment closed, study ongoing · Completion pushed from Oct 31, 2026 to May 30, 2027 · Eligibility criteria expanded, about 11 words · 1 more Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Completion pushed from Oct 31, 2026 to May 30, 2027
    • Eligibility criteria expanded, about 11 words
    • Site details revised at 2 of 2 sites
  2. Enrollment target: 45 to 75v5
  3. Study sites: 1 to 2 Primary completion date: Nov 30, 2025 to Mar 31, 2026v4 Show 1 more changeShow less
    • Primary completion date: Nov 30, 2025 to Mar 31, 2026
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 16, 2025 to Sep 24, 2025 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Sep 16, 2025 to Sep 24, 2025
    • Site details revised
  5. Start date: Jun 1, 2025 to Sep 16, 2025 Primary completion date: Oct 31, 2025 to Nov 30, 2025v2 Show 1 more changeShow less
    • Primary completion date: Oct 31, 2025 to Nov 30, 2025
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions. * What severe problems, if any, occur because of the use of the Stratagen Quantitative Prostate MRI Platform? * Can the data collected be used to measure quantitative MRI parameters? Participants will: \- Receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.
Trial Details
NCT Number NCT06985238
Lead Sponsor Stratagen Bio, Inc.
Conditions Prostate Cancer
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov